AbbVie bets on Alzheimer's immunotherapy with big biotech deal

(Reuters) - U.S. drugmaker AbbVie is betting on the potential of the body's immune system to fight Alzheimer's by signing a drug development deal worth more than $200 million with unlisted biotech company Alector.